EWA
TCRT icon

Exencial Wealth Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Exencial Wealth Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,139
Closed -$311K – 481
2021
Q3 		$311K Buy
1,139
+86
+8% +$26.3K 0.01% 280
2021
Q2 		$417K Buy
1,053
+107
+11% +$49.9K 0.02% 341
2021
Q1 		$511K Buy
946
+332
+54% +$207K 0.03% 275
2020
Q4 		$232K Buy
+614
New +$244K 0.02% 344
2017
Q1 		– Sell
-102
Closed -$82K – 166
2016
Q4 		$82K Buy
+102
New +$91.9K 0.03% 163

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Exencial Wealth Advisors's TCRT Position: Q4 2021 in Review

Exencial Wealth Advisors sold out of Alaunos Therapeutics (TCRT) in Q4 2021, closing a stake of 1,139 shares — an estimated $311K sold.

Exencial Wealth Advisors first reported a position in TCRT in Q4 2016 and held it in 5 quarters. The position peaked at $511K in Q1 2021. 165 funds tracked by Wall St. Rank hold TCRT as of Q4 2021.

  • Exencial Wealth Advisors reported no remaining Alaunos Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Exencial Wealth Advisors sold 1,139 Alaunos Therapeutics shares in Q4 2021, an estimated $311K.
  • Exencial Wealth Advisors first reported a position in Alaunos Therapeutics in Q4 2016 and held it in 5 quarters.
  • Exencial Wealth Advisors's Alaunos Therapeutics position peaked at $511K in Q1 2021.
  • 165 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2021.

Based on Exencial Wealth Advisors's 13F filing for Q4 2021, filed 10 Feb 2022.